GSGene H. Stollerman

Gene H. Stollerman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Latest Publications

  • Open Access

    Group A streptococcal pharyngitis and penicillin G.

    by Gene H. Stollerman

    TO THE EDITOR—In the December 2006 issue of Clinical Infectious Diseases, Kaplan et al. [1] presented in vitro experiments that support the well-known fact that penicillin does not penetrate into cells very well and, therefore, does not kill intracellular bacteria. Their experiments were made by selecting 16 virulent variants of several group A streptococcal (GAS) M types. They omitted studies of less virulent strains that remained within the host epithelial cells for >24 h. Their ingested virulent strains survived penicillin treatment for several hours but then disrupted the host cells. In contrast, the macrolides entered the host cells promptly, killing the GAS sooner, so that the host cells survived longer. What is the clinical significance of these findings to which the authors allude?


    • 1 October 2002
      • Vol. 93  (5) , 371-87

    Current issues in the prevention of rheumatic fever.

    by G H Stollerman

    Variation in strain virulence helps to account for the wide spectrum of group A streptococcal diseases and for their striking epidemiological variation. Recent studies of the genetic control of the expression of the virulence factors of group A streptococci (GAS) are beginning to illuminate such variation. Although still obscure, the pathogenesis of acute rheumatic fever (RF) requires primary infection of the throat by highly virulent GAS strains. Those that have clearly caused RF contain large hyaluronate capsules and extended M-protein molecules. The M molecule contains some epitopes cross-reactive with host tissues, and also has superantigenic properties like the secreted GAS erythrogenic toxins. In settings where ARF has become rare, GAS pharyngitis continues to be quite common but is most often caused by relatively attenuated strains. These, however, may colonize the throat avidly, and often stubbornly. GAS "skin strains" that cause pyoderma (impetigo) are molecularly distinct from "throat strains". Although they may secondarily colonize and infect the throat, the pyoderma strains are generally less virulent and are not rheumatogenic. Some skin strains, however, may cause acute glomerulonephritis. The diagnosis, treatment and prevention of GAS pharyngitis is reviewed in relation to the varying prevalence of RF in different geographical and social settings.


  • Open Access

    Rheumatic Fever in the 21st Century

    by Gene H. Stollerman

    In the first half of the twentieth century, the group A streptococcus (GAS) was established as the sole etiologic agent of acute rheumatic fever (ARF


    • 18 July 2001
      • Vol. 53  (1) , 25-34

    Can we eradicate rheumatic fever in the 21st century?

    by G H Stollerman

    In the latter half of the 20th century, the clinical importance of variation in the virulence of strains of GAS has been clearly demonstrated. Although still obscure, the pathogenesis of ARF requires immunologically significant infection of the throat by virulent GAS strains. These strains contain large hyaluronate capsules and large M-protein molecules. The latter contain epitopes cross-reactive with host tissues, and also contain superantigenic toxic moieties. In areas where ARF has become rare, GAS pharyngitis continues to be common but is caused predominantly by GAS strains of relatively low virulence. These, however, may colonize the throat avidly and stubbornly. Molecularly distinct pyoderma strains may cause acute glomerulonephritis, but they are not rheumatogenic even though they may secondarily infect the throat. In developing countries with a very high incidence of rheumatic heart disease, identification of the prevalent rheumatogenic GAS strains and development of a multivalent vaccine against them is currently an interesting strategy. Pending vaccine development, intense primary and secondary penicillin prophylaxis should continue to be sharply focused on populations with the highest prevalence of RHD as such measures may often succeed in driving away the most virulent rheumatogenic clones of GAS from their midst.